Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387992 | 1.00 | CYP19A1 (0.41) | CYP19A1DDB1CRBNDGAT1TDP2 | |
| SCHEMBL3652436 | 0.84 | SMN1; SMN2 (0.41) | DGAT1TAAR1 | |
| SCHEMBL19390846 | 0.83 | ALDH1A1 (0.39) | TAAR1 | |
| SCHEMBL1464332 | 0.83 | TDP1 (0.42) | CYP19A1GSK3BBACE1 | |
| SCHEMBL14830081 | 0.83 | ALDH1A1 (0.39) | TAAR1 | |
| SCHEMBL1463116 | 0.83 | TDP1 (0.42) | CYP19A1GSK3BBACE1 | |
| SCHEMBL1273854 | 0.82 | ALDH1A1 (0.39) | DDB1CRBNBACE1 | |
| SCHEMBL3398180 | 0.82 | ALDH1A1 (0.39) | DDB1CRBNBACE1 | |
| SCHEMBL2387285 | 0.78 | LMNA (0.44) | CRBN | |
| SCHEMBL7225598 | 0.76 | ABCC9 (0.37) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | CYP19A1 4306/4885DDB1 1825/4885CRBN 3683/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | CYP19A1 3117/4885DDB1 2003/4885CRBN 4451/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | CYP19A1 4306/4885DDB1 1825/4885CRBN 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.